Federal Contractor Profile
Emergent Product Development Gaithersburg INC.
$2.4B obligated·15 awards·2 agencies·6 NAICS
Federal Contracts
Showing contracts 1–50 of 59 total. Sorted by action date, most recent first. Excludes $0 modifications.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Sep 5, 2025 | Department of Health and Human ServicesASPR/ORM-SNS | 75A50119C00071 | 325414 | ACAM2000, SMALLPOX (VACCINIA) VACCINE, LIVE (ACAM) | $56M |
| Aug 29, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600030C | 541711 | IGF::OT::IGF | $30M |
| Jan 10, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123C00037 | 541714 | MEDICAL COUNTERMEASURES (MCM) THAT CAN BE DEPLOYED IN THE EVENT OF A FILOVIRUS OUTBREAK ARE A CRUCIAL COMPONENT TO THE UNITED STATES GOVERNMENT?S (USG?S) OUTBREAK RESPONSE PLAN. BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) IS SEEKIN | $17M |
| Dec 12, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600030C | 541711 | IGF::OT::IGF | $50M |
| Aug 30, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123C00037 | 541714 | MEDICAL COUNTERMEASURES (MCM) THAT CAN BE DEPLOYED IN THE EVENT OF A FILOVIRUS OUTBREAK ARE A CRUCIAL COMPONENT TO THE UNITED STATES GOVERNMENT?S (USG?S) OUTBREAK RESPONSE PLAN. BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) IS SEEKIN | $42M |
| Jun 28, 2024 | Department of Health and Human ServicesASPR/ORM-SNS | 75A50119C00071 | 325414 | ACAM2000, SMALLPOX (VACCINIA) VACCINE, LIVE (ACAM) | $100M |
| Jun 26, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600030C | 541711 | IGF::OT::IGF | $30M |
| Nov 21, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600030C | 541711 | IGF::OT::IGF | $75M |
| Jul 31, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123C00037 | 541714 | MEDICAL COUNTERMEASURES (MCM) THAT CAN BE DEPLOYED IN THE EVENT OF A FILOVIRUS OUTBREAK ARE A CRUCIAL COMPONENT TO THE UNITED STATES GOVERNMENT?S (USG?S) OUTBREAK RESPONSE PLAN. BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) IS SEEKIN | $60M |
| Jun 16, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600030C | 541711 | IGF::OT::IGF | $75M |
| May 19, 2023 | Department of Health and Human ServicesASPR/ORM-SNS | 75A50119C00071 | 325414 | ACAM2000, SMALLPOX (VACCINIA) VACCINE, LIVE (ACAM) | $120M |
| Mar 30, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600030C | 541711 | IGF::OT::IGF | $4.5M |
| Mar 13, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201400038C | 541712 | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | $476K |
| Oct 27, 2022 | Department of DefenseARMY MED RES ACQ ACTIVITY | W81XWH19C0193 | 541715 | CREATION OF AN FDA APPROVED ANALGESIC KETAMINE DRUG WITH AUTO INJECTOR DELIVERY SYSTEM. | $6.8M |
| Aug 24, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201700001C | 541711 | IGF::OT::IGF - ADVANCING STABILIZED ISOAMYL NITRITE FOR INTRANASAL TREATMENT OF CYANIDE EXPOSURE | $6.8M |
| Jul 1, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201000059C | 541711 | TAS::75 0140::TAS ADVANCED DEVELOPMENT OF RECOMBINANT PROTECTIVE ANTIGENT (RPA) ANTHRAX VACCINE CAN 1990087 | $8.0M |
| May 19, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201400038C | 541712 | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | $69K |
| Sep 30, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600030C | 541711 | IGF::OT::IGF | $399M |
| Jul 5, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119C00071 | 325414 | ACAM2000, SMALLPOX (VACCINIA) VACCINE, LIVE (ACAM) | $182M |
| Jun 10, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272200700034C | 541710 | BIOMEDICAL (BASIC) | $749K |
| Jun 10, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272200800040C | 541711 | NEW AWARD UNDER BAA NIH-NIAID-DMID-08-20. THIS IS ONE OF FOUR AWARDS UNDER THIS BAA. | $1.4M |
| Jun 8, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272200800051C | 541712 | BIOMEDICAL (ADVANCED) | $2.6M |
| Apr 28, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSD200200824959I | 325414 | ACAMBIS, 200-2008-24959 | $2.8M |
| Mar 24, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119C00071 | 325414 | ACAM2000, SMALLPOX (VACCINIA) VACCINE, LIVE (ACAM) | $753K |
| Mar 18, 2021 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | W81XWH19C0193 | 541715 | CREATION OF AN FDA APPROVED ANALGESIC KETAMINE DRUG WITH AUTO INJECTOR DELIVERY SYSTEM. | $4.4M |
| Nov 17, 2020 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | W81XWH19C0193 | 541715 | CREATION OF AN FDA APPROVED ANALGESIC KETAMINE DRUG WITH AUTO INJECTOR DELIVERY SYSTEM. | $1.0M |
| Sep 18, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201000035C | 541711 | TAS::75 0885::TAS DEVELOPMENT OF TECHNOLOGIES TO FACILITATE THE USE OF, AND RESPONSE TO, BIODEFENSE VACCINES | $2.7M |
| Jul 13, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600030C | 541711 | IGF::OT::IGF | $258M |
| May 28, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119C00071 | 325414 | ACAM2000, SMALLPOX (VACCINIA) VACCINE, LIVE (ACAM) | $176M |
| Sep 26, 2019 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | W81XWH19C0193 | 541715 | CREATION OF AN FDA APPROVED ANALGESIC KETAMINE DRUG WITH AUTO INJECTOR DELIVERY SYSTEM. | $5.7M |
| Sep 9, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201700001C | 541711 | IGF::OT::IGF - ADVANCING STABILIZED ISOAMYL NITRITE FOR INTRANASAL TREATMENT OF CYANIDE EXPOSURE | $12M |
| Aug 30, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119C00071 | 325414 | ACAM2000, SMALLPOX (VACCINIA) VACCINE, LIVE (ACAM) | $170M |
| Aug 15, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201400038C | 541712 | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | $2.2M |
| Jul 30, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600030C | 541711 | IGF::OT::IGF | $261M |
| Jun 7, 2019 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA114C0122 | 541711 | IGF::OT::IGF, THE FIRST ORAL ANTIBIOTIC FOR THE TREATMENT OF ACUTE MELIODOSIS AND SELECT AGENTS" FOR MODIFICATIONS P00011, 12 AND 13. | $400K |
| Apr 17, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201700001C | 541711 | IGF::OT::IGF - ADVANCING STABILIZED ISOAMYL NITRITE FOR INTRANASAL TREATMENT OF CYANIDE EXPOSURE | $1.5M |
| Apr 12, 2019 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA114C0122 | 541711 | IGF::OT::IGF, THE FIRST ORAL ANTIBIOTIC FOR THE TREATMENT OF ACUTE MELIODOSIS AND SELECT AGENTS" FOR MODIFICATIONS P00011, 12 AND 13. | $308K |
| Mar 13, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50119P00020 | 325414 | DILUENT REPLACEMENT | $12M |
| Feb 11, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201400038C | 541712 | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | $1.6M |
| Jan 31, 2019 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA114C0122 | 541711 | IGF::OT::IGF, THE FIRST ORAL ANTIBIOTIC FOR THE TREATMENT OF ACUTE MELIODOSIS AND SELECT AGENTS" FOR MODIFICATIONS P00011, 12 AND 13. | $2.2M |
| Sep 11, 2018 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201500004C | 541711 | IGF::OT::IGF FOR OTHER FUNCTIONSTHIS CONTRACT IS FOR THE ADVANCED DEVELOPMENT OF NUTHRAX (ANTHRAX VACCINE ABSORBED WITH CPG 7909) OR AV7909 | $3.8M |
| Aug 29, 2018 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201600030C | 541711 | IGF::OT::IGF | $5.0M |
| Aug 13, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201400038C | 541712 | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | $57K |
| Jun 8, 2018 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA114C0122 | 541711 | IGF::OT::IGF, THE FIRST ORAL ANTIBIOTIC FOR THE TREATMENT OF ACUTE MELIODOSIS AND SELECT AGENTS" FOR MODIFICATIONS P00011, 12 AND 13. | $3.5M |
| Mar 22, 2018 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA114C0122 | 541711 | IGF::OT::IGF, THE FIRST ORAL ANTIBIOTIC FOR THE TREATMENT OF ACUTE MELIODOSIS AND SELECT AGENTS" FOR MODIFICATIONS P00011, 12 AND 13. | $100K |
| Mar 14, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | HHSN272201400038C | 541712 | IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS | $2.4M |
| Dec 8, 2017 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA114C0122 | 541711 | IGF::OT::IGF, THE FIRST ORAL ANTIBIOTIC FOR THE TREATMENT OF ACUTE MELIODOSIS AND SELECT AGENTS" FOR MODIFICATIONS P00011, 12 AND 13. | $1.2M |
| Nov 21, 2017 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | HDTRA114C0122 | 541711 | IGF::OT::IGF, THE FIRST ORAL ANTIBIOTIC FOR THE TREATMENT OF ACUTE MELIODOSIS AND SELECT AGENTS" FOR MODIFICATIONS P00011, 12 AND 13. | $100K |
| Nov 16, 2017 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201500004C | 541711 | IGF::OT::IGF FOR OTHER FUNCTIONSTHIS CONTRACT IS FOR THE ADVANCED DEVELOPMENT OF NUTHRAX (ANTHRAX VACCINE ABSORBED WITH CPG 7909) OR AV7909 | $4.8M |
| Sep 15, 2017 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO100201700001C | 541711 | IGF::OT::IGF - ADVANCING STABILIZED ISOAMYL NITRITE FOR INTRANASAL TREATMENT OF CYANIDE EXPOSURE | $13M |
Get Alerted Before Emergent Product Development Gaithersburg INC.'s Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start Free